| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
A DOD Health Agency-funded adaptive platform trial for alternative treatments for PTSD will test SLS-002 on some 600 active-duty service members and veterans. The intranasal racemic ketamine was developed by biotech company Seelos Therapeutics (NASDAQ:SEEL).
The new Phase 2 study will use an adaptive platform trial design involving a 30-day screening period, a 12-week treatment period, and a four-week follow-up to assess safety, tolerability and efficacy of multiple doses of SLS-002 paired with therapy. Read more HERE.
Next-generation psychedelics biotech Cybin Inc. (NYSE:CYBN) released the full Phase 2 trial results of its deuterated psilocybin derivative CYB003 for Major Depressive Disorder (MDD.) Although a relatively small trial, outcomes for the novel psychedelic are so far showing strong treatment efficacy after a single dose and “a clear incremental benefit” following a second one.
See new topline follow-up data HERE.
Clearmind Medicine Inc. (NASDAQ:CMND) released results from its pre-clinical trial of the combination therapy. The treatment includes Clearmind's MEAI, a proprietary psychedelic treatment for various addictions, obesity and metabolic disorders, and depression, and SciSparc Ltd's (NASDAQ:SPRC) Palmitoylethanolamide (PEA), an anti-inflammatory agent and the active ingredient of its proprietary CannAmide. Learn more HERE.
Clearmind has recently undergone a 1-for-30 reverse stock split of its issued and outstanding ordinary shares, effective starting Nov. 28, as a means to regain compliance with Nasdaq’s minimum bid price rule.
Beckley Retreats, a science-backed psilocybin retreats and holistic wellbeing company, is officially launching its Signature Program for Personal Discovery and Transformation, “an 11-week curriculum of preparation and integration support to help guests achieve the most significant benefit from their six-day psilocybin retreats” in Jamaica and the Netherlands.
Under the umbrella of Amanda Feilding’s Beckley Foundation family of brands, Beckley Retreats has access to modern psychedelic science, implementing this research into its programming and protocols and collaborating in research and datasets toward helping set a precedent and best practices for the modern use of psychedelics. Program details HERE.
Austin-based ketamine therapy provider Mindbloom is launching its Mastermind Series, the first-of-its-kind, expert-led psychedelic therapy program for overcoming severe mental and emotional health challenges.
With a new monthly release every month, each episode was developed jointly with a leading expert in the field and combines specialized instruction with ketamine therapy to enhance neuroplasticity and enable lasting change.
The first episode, “Recovering from Rejection and Failure,” is led by emotional health expert, psychologist and best-selling author Dr. Guy Winch who will provide “emotional first aid” and skills paired with ketamine therapy. Find out more HERE.
Seelos Therapeutics (NASDAQ:SEEL) launched a $5.55 million public offering, and stock dropped 35%.
Numinus Wellness (OTC:NUMIF) reported its Q4 and full-year 2023 results, greatly reduced cash burn rate included.
Red Light Holland (OTC:TRUFF), with a $12 million cash balance and revenue up 33%, remains 'confident' in its business strategy.
Irwin Naturals’ (OTC:IWINF) Q3 was led by cannabis and psychedelics buzz, despite falling revenue & surging losses.
Check out our psychedelics states update, this edition featuring Kentucky, Arizona, Wisconsin, California, Washington, Massachusetts & Alaska.
Worldwide, latest in Australia and New Zealand and in Norway and Finland.
Psychedelic cinema: 10 trippy holiday movies that warp reality.
See Also: Last Week's Edition Of 'Psyched'
AdvisorShares Psychedelics ETF (NYSE:PSIL) opened Monday, November 27 at $1.43 (vs. prior weeks’ openings at $1.25 and $1.29)
On Friday, Dec. 1 it closed at $1.33 (vs. prior closings at $1.42 and $1.32.)
Week’s highest was opening price of $1.43 (vs. prior weeks’ highests at $1.44 and $1.37.)
Week’s lowest was $1.27 on Thursday, Nov. 30 (vs. prior weeks’ lowest points at $1.25 and $1.27.)
GH Research (NASDAQ:GHRS) closed at $6.40, vs. immediately prior closings at $6.58 and $6.44.
COMPASS Pathways (NASDAQ:CMPS) closed at $6.10, vs. prior closings at $6.46 and $6.01.
Incannex Healthcare (NASDAQ:IXHL) closed at $5.23, a spectacular jump from prior closings at $0.97 and $0.91
Clearmind Medicine (NASDAQ:CMND) closed at $4.14, also an ostensible high considering prior closings at $3.10 and $3.82.
Mind Medicine (MindMed) (NASDAQ:MNMD) closed at $3.52, vs. prior closings at $3.03 and $2.59.
Enveric Biosciences (NASDAQ:ENVB) closed at $1.68, vs. prior closings at $1.47 and $1.52.
Silo Pharma (NASDAQ:SILO) closed at $1.45, vs. prior closings at $1.82 and $1.50.
Bright Minds Biosciences (NASDAQ:DRUG) closed at $1.42, vs. prior closings at $1.49 and $1.26.
Seelos Therapeutics (NASDAQ:SEEL) closed at $1.38, vs. prior closings at $3.21 and $3.82.
Atai Life Sciences (NASDAQ:ATAI) closed at $1.12, vs. prior closings at $1.09 and $1.11.
Stock trading numbers above according to Benzinga Pro, our all-the-information-you-need streaming platform helping you invest smarter - Come join us and see for yourself!
Posted In: ATAI CMND CMPS CYBN DRUG ENVB GHRS IWINF IXHL MNMD NUMIF PSIL SEEL SILO SPRC TRUFF
